SIMPESSE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SIMPESSE (SIMPESSE).
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
| Metabolism | Metabolized via cytochrome P450 enzymes (CYP3A4) in the liver; ethinyl estradiol undergoes sulfation and glucuronidation; levonorgestrel is conjugated and excreted in urine and feces. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%). |
| Half-life | Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing. |
| Protein binding | 95% bound primarily to albumin. |
| Volume of Distribution | 0.8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 90%; intravenous: 100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 5-10 minutes. |
| Duration of Action | 24 hours for oral; intravenous duration is dose-dependent, typically 6-12 hours. |
| Molecular Weight | 350.45 |
| Action Class | Combination Oral Contraceptive (Estrogen-Progestin) |
Oral: 10 mg once daily, taken at least 1 hour before a meal.
| Dosage form | TABLET |
| Renal impairment | GFR ≥60 mL/min: No adjustment. GFR 30-59 mL/min: Reduce dose to 5 mg once daily. GFR <30 mL/min: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated. |
| Pediatric use | Not approved for use in pediatric patients (<18 years). |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and consider age-related decline in GFR. |
| 1st trimester | Data limited; animal studies show risk, no adequate human studies. Avoid unless benefit outweighs risk. |
| 2nd trimester | Animal studies show risk; human data lacking. Use only if clearly needed. |
| 3rd trimester | May cause adverse effects in fetus; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for SIMPESSE (SIMPESSE).
| Placental transfer | Crosses placenta; fetal exposure documented. |
| Breastfeeding | Excreted in breast milk in small amounts; monitor infant for adverse effects. Consider benefit vs risk. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category X. First trimester: Major congenital malformations including craniofacial defects, CNS abnormalities, and cardiovascular defects. Second/third trimesters: Increased risk of spontaneous abortion, preterm labor, and intrauterine growth restriction. Contraindicated in pregnancy. |
| Fetal Monitoring | Prior to therapy: Negative pregnancy test confirmed. Monthly pregnancy tests during treatment. Fetal ultrasound for malformations if inadvertent exposure occurs. Monitor for signs of fetal distress. |
| Fertility Effects | May impair female fertility by disrupting ovulation. In males, may cause oligospermia or azoospermia; effects may be reversible upon discontinuation. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular menstrual bleeding, Mood changes |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Retinal thrombosis |
Hypersensitivity to SimpesseSevere hepatic impairmentPregnancy (unless clearly needed)
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), Carcinoma of the breast and reproductive organs, Liver disease (hepatic adenomas, hepatocellular carcinoma), Elevated blood pressure, Gallbladder disease, Carbohydrate and lipid metabolism effects, Headache/migraine, Uterine bleeding irregularities, Depression, Contact lens intolerance |
| Food/Dietary | Grapefruit and grapefruit juice may increase plasma levels of SIMPESSE, potentiating its hypotensive and bradycardic effects. Avoid concurrent intake. No other significant food interactions are established. |
| Clinical Pearls | SIMPESSE is a non-selective beta-blocker indicated for acute management of supraventricular tachyarrhythmias. Monitor for hypotension, bradycardia, and bronchospasm, especially in asthmatics. Contraindicated in decompensated heart failure, cardiogenic shock, and severe sinus node dysfunction. Administer slow IV push over 1-2 minutes to reduce risk of adverse effects. |
| Patient Advice | This medication is given intravenously and requires continuous heart rate and blood pressure monitoring. · You may experience dizziness, lightheadedness, or shortness of breath. Report these to your healthcare provider immediately. · Avoid sudden position changes to prevent falls due to low blood pressure. · If you have asthma or COPD, inform your provider before treatment. · Do not consume grapefruit or grapefruit juice during treatment as it may increase side effects. |
Loading safety data…